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Targeting Mitochondrial
Oxidative Stress in Heart Failure
Throttling the Afterburner*
Christoph Maack, MD, Michael Böhm, MD
Homburg, Germany
Oxidative stress contributes to various cardiovascular dis-
eases and aging and was causally linked to the progression of
heart failure (1,2). Among the most relevant sources for
reactive oxygen species (ROS) are nicotinamide adenine
dinucleotide phosphate (NADPH) oxidases and mitochon-
dria (1,3–7). The ROS impair excitation-contraction cou-
pling, cause arrhythmias, and contribute to cardiac remod-
elling by inducing cardiac hypertrophy, apoptosis, necrosis,
and fibrosis (1,8,9). However, antioxidative interventions
(e.g., vitamin E) in patients with cardiovascular diseases
have yielded disappointing results so far (10).
See page 73
In this issue of the Journal, Dai et al. (11) report that
specifically targeting mitochondrial ROS production with
the synthetic Szeto-Schiller peptide SS-31 prevents cardiac
hypertrophy, fibrosis, and left ventricular diastolic dysfunc-
tion in a model of angiotensin II (and hypertension)
induced cardiomyopathy. SS-31 is a dimethyltyrosine-
containing peptide that scavenges various ROS (i.e., hydro-
gen peroxide [H2O2], superoxide [
.O2
], and hydroxyl
radicals) (12). Due to its positive charge, it accumulates
1,000-fold in (negatively charged) mitochondria (12).
After initial in vitro studies, in which the antioxidative
capacity of SS-31 was protected from ROS-induced mito-
chondrial dysfunction and apoptosis, SS-31 was used in
several in vivo models of diseases associated with mitochon-
drial oxidative stress, such as neurodegenerative and meta-
bolic diseases, renal dysfunction, and myocardial ischemia/
reperfusion injury (12,13).
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disclose.Two aspects about this elegant study are particularly
remarkable and deserve further discussion. First, cardiac
hypertrophy and dysfunction were induced by infusion
of angiotensin II, a canonical activator of NADPH
oxidase, and yet, cardiac remodeling was prevented by
inhibiting mitochondrial ROS production, suggesting
that mitochondria might “amplify” NADPH oxidase-
derived ROS production. Second, nontargeted ROS
scavenging with N-acetyl cysteine (NAC) was less effec-
tive than mitochondria-targeted scavenging with SS-31,
implying that primarily the mitochondrial component of
cellular ROS production induces maladaptive cardiac
remodeling.
How can these results be explained? In mitochondria, the
Krebs cycle generates NADH, which delivers electrons to
the electron transport chain (ETC) (Fig. 1), inducing
translocation of protons across the inner mitochondrial
membrane. This establishes a membrane potential (m)
that fuels the F1F0-ATPase to generate adenosine triphos-
hate (ATP). At the ETC, electrons can leak to oxygen to
roduce .O2
, which is dismutated to H2O2 by manganese-
dependent superoxide dismutase (Mn-SOD). H2O2, in
urn, is detoxified by enzymes that require NADPH, and
ADPH is regenerated by enzymes that derive their sub-
trates from the Krebs cycle (Fig. 1). Accordingly, an
quilibrium exists between NADH/NAD and NADPH/
NADP (14).
Two principal scenarios can be envisioned that favor
ncreased mitochondrial ROS-formation: 1) increased for-
ation of .O2
 at the ETC; and 2) decreased elimination of
.O2
 or H2O2 in the mitochondrial matrix. In heart failure,
the first scenario occurs when modifications of ETC com-
plexes (disturbed stochiometry, posttranslational modifica-
tions, and the like) hamper electron flux along the ETC,
prematurely “deviating” electrons from reduced ETC com-
plexes to oxygen to provoke excess .O2
 formation (2). In
fact, Ide et al. (5) reported a functional block at complex I
in mitochondria of failing dog hearts, giving rise to in-
creased .O2
 formation. Considering the second scenario,
activity of Mn-SOD is reduced in heart failure, and al-
though glutathione peroxidase activity was unchanged in
homogenized samples of human failing hearts (15), its
activity in intact cells and mitochondria is dynamically
governed by the availability of NADPH and glutathione
(3,14). Because NADPH regeneration depends on Krebs
cycle products (Fig. 1) and rate-limiting Krebs cycle
enzymes are activated by calcium (Ca2), mitochondrial
Ca2 uptake dynamically controls the redox state of
NAD(P)H in working cardiac myocytes and thus H2O2
formation (3). Because in failing cardiac myocytes, mi-
tochondrial Ca2 uptake is hampered, NAD(P)H is
ore oxidized and H2O2 formation is increased (3,16).
Activation of ion channels in the inner mitochondrial
embrane—such as: 1) the permeability transition porePTP); 2) the inner membrane anion channel (IMAC);
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Mitochondria and Heart Failure June 28, 2011:83–6or 3) the mitochondrial ATP-dependent K-channel
(mitoKATP)— depolarizes m, necessitating increased
lectron flux along the ETC (at the cost of NADH) to
aintain m and ATP production (Fig. 1). Thus, opening
f these channels could potentially increase ROS formation
ue to oxidation of NAD(P)H. Interestingly, these 3
hannels have in common that they can be activated by
OS themselves. Furthermore, anionic .O2
 can be re-
leased from mitochondria via the PTP or the IMAC but not
via mitoKATP (Fig. 1). Accordingly, the PTP and IMAC
lay central roles in a phenomenon coined “ROS-induced
OS release,” in which ROS trigger oscillations of m
that can induce reperfusion arrhythmias and, when sus-
tained, lead to cell death (9,17,18). By contrast, activation of
mitoKATP during ischemic preconditioning transiently in-
creases mitochondrial ROS formation that protects from
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Figure 1 SS-31 Specifically Targets Mitochondria as “Afterburn
Cytosolic reactive oxygen species (ROS) from various sources can activate () the
KATP-channel in the inner mitochondrial membrane. Although the PTP is a large po
larger molecules, the IMAC is permeable for anions (An) that are released from n
anionic .O2
 in a process termed “ROS-induced ROS release.” Activation of PTP, I
increased electron (e) flux along the electron transport chain (ETC) to maintain 
gen peroxide (H2O2) via glutathione reductase (GR) and peroxidase (GPX). NADH is
pally favors H2O2 formation. Mitochondrial ROS activate mitogen-activated protein
ischemia/reperfusion (I/R) but on the other hand induce hypertrophy and fibrosis
tion via ROS-induced ROS release, which induced maladaptive cardiac remodelling
cysteine (NAC) prevented remodelling. Changes in heart failure are indexed wit
GSH/GSSG  reduced/oxidized glutathione; IDPm  mitochondrial NADP
-dep
Mn2-dependent superoxide dismutase; Nnt  nicotinamide nucleotide transhy
XO  xanthine oxidase.ischemia/reperfusion-induced damage by activating redox- tsensitive signaling pathways that converge on preventing
PTP activation (19,20).
In this context, Kimura et al. (21) recently proposed that
angiotensin II, by stimulating NADPH oxidase-derived
.O2
 production, could activate mitoKATP to trigger mito-
hondrial ROS production that provided protection against
schemia/reperfusion injury in the short term. Here, Dai et
l. (11) demonstrate that sustained angiotensin II-induced
OS production triggers maladaptive remodelling that
nduces diastolic dysfunction. Because blockade of either the
TP or IMAC reduced angiotensin II-induced ROS pro-
uction in isolated cardiac myocytes, the authors concluded
hat “ROS-induced ROS release” from mitochondria was
he mechanism by which NADPH oxidase-derived ROS
roduction is amplified by mitochondria. In this context, it
s somewhat surprising that activation (rather than inhibi-
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is permeable for ions (along their respective electrochemical gradients) and
ely polarized mitochondria to the cytosol. Thus, both channels can release
nd/or KATP dissipates mitochondrial membrane potential (m), necessitating
d adenosine triphosphate (ATP) production. NADPH is required to detoxify hydro-
uilibrium with NADPH, and thus oxidation of NADH (by m dissipation) princi-
kinases, such as p38 or ERK1/2, which on the one hand protect from
long run. In the present study, angiotensin II increased mitochondrial ROS forma-
eted inhibition of mitochondrial ROS by SS-31 but not nontargeted N-acetyl
arrows (12). Novel aspects of the present study are highlighted in blue.
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investigation. Notwithstanding, in human failing myocar-
dium, NADPH oxidase activity is increased (6) and mi-
toKATP are endogenously activated (8), which would sup-
ort the concept of ROS-induced activation of mitoKATP.
Although this endogenous activation protected from
acute ROS-induced contractile dysfunction (8) (a sce-
nario that occurs during ischemia/reperfusion and in-
duces “myocardial stunning”), energetic mismatch and
mitochondrial oxidative stress might be adverse long-
term consequences of mitoKATP-induced dissipation of
m that could trigger maladaptive remodelling, as
uggested by the present study.
The second important aspect of the present study is that
argeted mitochondrial ROS scavenging with SS-31 or
itochondria-targeted catalase reduced remodelling,
hereas nontargeted (ubiquitous) ROS scavenging with
AC had no effect. This is in agreement with the lack of
enefit provided by nontargeted vitamin E treatment in the
linical arena (10) and supports the general concept of
ompartmentalized signaling, which is increasingly recog-
ized for many second messengers, such as Ca2 or cyclic
nucleotides, and might apply to NADPH oxidase-related
ROS signaling as well. This concept implies that close
vicinity of signaling molecules provides local control over
second messengers that might not necessarily reflect
changes in their global intracellular concentrations. In this
regard, nontargeted ROS scavenging with NAC might be
less efficient to scavenge ROS in such microdomains,
whereas SS-31—which accumulates manifold at the site of
ROS formation in mitochondria (at the inner mitochondrial
membrane [12])—might be more efficient.
Along similar lines, 2 isoforms of NADPH oxidase exist
in the heart, Nox2 and Nox4. Although Nox2 is located in
the cell membrane, Nox4 is localized in perinuclear endo-
plasmic reticulum and/or mitochondria (4,7). Interestingly,
although Nox2 mediates maladaptive cardiac remodelling in
response to angiotensin II (22), Nox4 upregulation in heart
failure might play a rather protective role by enhancing
angiogenesis (Fig. 1) (4), although conflicting data exist (7).
In the present study, Nox4 was upregulated in response to
angiotensin II infusion, in agreement with other cardiac
stresses in previous studies (4,7). If Nox4-related ROS
production indeed protects from the development of heart
failure (4), this might be another potential explanation why
nontargeted ROS scavenging with NAC was less effective
than mitochondria-targeted scavenging with SS-31, because
NAC might scavenge both maladaptive (Nox2- and
mitochondria-related) and protective (Nox4-derived) ROS.
Clearly, these issues require further investigation, particu-
larly concerning the cellular localization of Nox4 signaling
and its role for cardiac remodeling (4,7).
In the study by Dai et al. (11), chronic angiotensin II
treatment induced diastolic dysfunction with preserved sys-
tolic function. Clinically, morbidity and mortality is simi-
larly adverse for patients with heart failure with eitherpreserved (HFpEF) or reduced ejection fraction (HFrEF),
and yet no effective treatment for HFpEF has been identi-
fied (23). Thus, there is an urgent need for novel therapeutic
options especially for patients with HFpEF. Although the
pathophysiological issues discussed in the preceding text
might apply to both systolic and diastolic heart failure, the
current data suggest that targeting mitochondrial ROS
might be a particularly interesting option in patients with
HFpEF.
Taken together, specific targeting of cellular microdo-
mains of ROS signaling might be a promising therapeutic
approach in heart failure. Future research should be directed
at further testing the therapeutic efficiency of SS-31 in
larger animal studies to translate the promising results from
rodents to heart failure in humans.
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